Interactive Wednesday Webinar on Effective Medical Communication
Medical communication is becoming increasingly important for payers, pharma, and healthcare professionals. NetworkPharma will host a webinar this week on [...]
New Guide on Successfully Using RWE in Drug Development Pipeline
Using real world evidence (RWE) continues to be a valuable alternative to the traditional clinical trial. A new guide from [...]
Can Improved QALYs Effectively Reduce Drug Prices?
Dan Ollendorf of Tuft’s Center for the Evaluation of Value and Risk in Health (CEVR) shared his thoughts on how [...]
ISPOR’s Value in Health Discusses Economic Solutions to COVID-19 Pandemic
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)’s Value in Health journal published a themed collection of articles on COVID-19 [...]
New Article Discusses 35 Oncology Drugs Receiving Accelerated Approval
An article published in the New England Journal of Medicine (NEJM) discusses 35 oncology drugs that received accelerated approval from [...]
Amgen Leader Discusses Future Trends for Medical Affairs Professionals
Last year, the Medical Affairs Professional Society (MAPS) and Vice President of Amgen Europe Medical Affairs Dr. Isma Benattia announced [...]
MAPS Podcast on Virtual and Hybrid Events as COVID-19 Restrictions Ease
Medical Affairs Professional Society (MAPS) recently hosted a podcast with support from Impetus Digital. Impetus Digital CEO and Co-Founder Natalie [...]
Non-Legislative and Legislative Actions Could Reduce High Prescription Drug Prices
Reducing prescription drug prices in the United States continues to be a point of contention. Although legislative measures are expected [...]
Cytel Blog on Applying Bayesian Methods to COVID-19 Clinical Trials
A Cytel blog post discusses how Bayesian methods have impacted COVID-19 vaccine clinical trials. Using Bayesian statistics can improve study [...]
Lead Author of PRISMA 2020 Statement Discusses Research and Publication Trends
In a recent discussion with Matt Page, lead author of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) [...]
ICER Publishes Draft Evidence Report on Alzheimer’s Disease Drug
The Institute for Clinical and Economic Review (ICER) published a Draft Evidence Report regarding Biogen’s aducanumab. The drug is designed to treat [...]
Model N and Global Pricing Innovations Partner to Improve Market Access
Model N and Global Pricing Innovations have announced a new partnership designed to improve market access. The companies are leaders [...]
PRMA Consulting Offers Concise Market Access Webinar
PRMA Consulting is offering a free 10-minute webinar on optimizing global and regional market access. The webinar will highlight common [...]
New Report Suggests Payer Profitability During COVID-19 Pandemic
A Kaiser Family Foundation brief points to increased profitability for payers during the COVID-19 pandemic. The research group noted that [...]
ISPOR Seeks Input Regarding Live Events
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is seeking your input regarding in-person events during its Europe 2021 [...]
JAMA Report on Reducing Prescription Drug Prices Using Legislation, Notes 159% List Price Increase in 11 Years
A new report discusses legislation that could reduce skyrocketing drug prices. Attempts at the state level have put forth unsupported [...]
BCG Report on Using RWE in Clinical Trials
A Boston Consulting Group (BCG) report discusses the benefits of real world evidence (RWE) in streamlining the clinical trial pipeline. [...]
Healthcare Communications Survey Seeks Your Input
The fourth yearly Healthcare Communications Workforce Insight Survey is taking responses. The survey was created by Paramount Recruitment along with [...]
New Report Claims Reducing Drug Prices Will Not Impact Innovation, Discusses HTA Solution
Patients for Affordable Drugs released a report on how lowering drug prices would fail to impact innovation. The authors note [...]
HealthVerity Discusses How the COVID-19 Pandemic Accelerated RWD and RWE Trends in Drug Development
The COVID-19 pandemic has hastened industry trends when it comes to using real world data (RWD) and real world evidence [...]
ICER’s Protocol on Unsupported Price Increases Discusses 250 Drugs
The Institute for Clinical and Economic Review (ICER) recently published a protocol detailing how it determines unjustified price increases. The [...]
Upcoming Virtual Discussion on Reducing High Prescription Drug Prices Without Impacting Innovation
Patients for Affordable Drugs will host a virtual session on overcoming high drug prices on May 18th at 7 PM [...]
New Report Offers Global Market Insight and Highlights Critical HEOR RWD Trends
A new report discusses health economics and outcomes research (HEOR) trends expected to impact the global economy for the next [...]
New Study Analyzes List and Net Prices of Diabetes Drugs
A new study considers the prices of three categories of drugs used in diabetes. The authors note an increase in [...]
Xcenda Leader Provides Insight on Biosimilars for Payers and Pharma
Managing Director Allen Lising of Xcenda’s FormularyDecisions shared his thoughts on biosimilars. He notes that when it comes to the [...]